Susan Chang

ORCID: 0000-0003-3521-364X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Glioma Diagnosis and Treatment
  • Radiomics and Machine Learning in Medical Imaging
  • RNA modifications and cancer
  • RNA Research and Splicing
  • RNA and protein synthesis mechanisms
  • Medical Imaging Techniques and Applications
  • Cancer Genomics and Diagnostics
  • Cancer-related cognitive impairment studies
  • Brain Metastases and Treatment
  • Cancer Treatment and Pharmacology
  • Cancer, Hypoxia, and Metabolism
  • Neuroblastoma Research and Treatments
  • Hedgehog Signaling Pathway Studies
  • Single-cell and spatial transcriptomics
  • Hip disorders and treatments
  • Advanced MRI Techniques and Applications
  • Cancer Research and Treatments
  • Monoclonal and Polyclonal Antibodies Research
  • Injury Epidemiology and Prevention
  • MRI in cancer diagnosis
  • Trauma and Emergency Care Studies
  • Total Knee Arthroplasty Outcomes
  • Advanced Electron Microscopy Techniques and Applications
  • Sarcoma Diagnosis and Treatment
  • AI in cancer detection

Neurological Surgery
2007-2025

University of California, San Francisco
2016-2025

University of San Francisco
2009-2024

Center for Neurosciences
2024

Monash University
2017-2021

Stanford Health Care
2017

University Hospital Heidelberg
2015

University of California, Los Angeles
2015

Center for Neuro-Oncology
2015

Heidelberg University
2015

Recent longitudinal studies of glioblastoma (GBM) have demonstrated a lack apparent selection pressure for specific DNA mutations in recurrent disease. Single-cell lineage tracing has shown that GBM cells possess high degree plasticity. Together this suggests phenotype switching, as opposed to genetic evolution, may be the escape mechanism explains failure precision therapies date. We profiled 86 primary-recurrent patient-matched paired specimens with single-nucleus RNA, single-cell...

10.1038/s43018-022-00475-x article EN cc-by Nature Cancer 2022-12-20

Roberts syndrome/SC phocomelia (RBS) is an autosomal recessive disorder with growth retardation, craniofacial abnormalities and limb reduction. Cellular alterations in RBS include lack of cohesion at the heterochromatic regions around centromeres long arm Y chromosome, reduced capacity, hypersensitivity to DNA damaging agents. caused by mutations ESCO2, which encodes a protein belonging highly conserved Eco1/Ctf7 family acetyltransferases that involved regulating sister chromatid cohesion....

10.1093/hmg/ddn116 article EN Human Molecular Genetics 2008-04-14

Abstract Background Alternative splicing is a rich source of tumor-specific neoantigen targets for immunotherapy. This holds promise glioblastomas (GBMs), the most common primary tumors adult brain, which are resistant to standard-of-care therapy. Although clinical trials enroll patients at recurrence, preclinical studies have been done with specimens from disease. There limited expression data GBMs recurrence and surprisingly little known about evolution patterns under Result We profile 37...

10.1186/s13059-021-02259-5 article EN cc-by Genome biology 2021-01-26

Isocitrate dehydrogenase (IDH)-mutant astrocytomas represent the most frequent primary intraparenchymal brain tumor in young adults, which typically arise as low-grade neoplasms that often progress and transform to higher grade despite current therapeutic approaches. However, genetic alterations underlying high-grade transformation disease progression of IDH-mutant remain inadequately defined. Genomic profiling was performed on 205 from 172 patients both initial treatment-naive recurrent...

10.1093/noajnl/vdaf024 article EN cc-by-nc Neuro-Oncology Advances 2025-01-01

Abstract BACKGROUND A major impediment to improving neuro-oncology outcomes is poor clinical trial accrual. METHODS We convened a multi-stakeholder group including Society for Neuro-Oncology, Response Assessment in patient advocacy groups, cooperative and other partners determine how we can improve RESULTS described selected factors contributing accrual possible solutions. focused on community factors, disparities, physician provider site organizational CONCLUSIONS will implement strategies...

10.1093/neuonc/noz175.574 article EN Neuro-Oncology 2019-11-01

Abstract Isocitrate dehydrogenase (IDH)-mutant gliomas are the most common malignant primary brain tumors in young adults. This condition imposes a substantial burden on patients and their caregivers, marked by neurocognitive deficits high mortality rates due to tumor progression, coupled with significant morbidity from current treatment modalities. Although surgery, radiation therapy, chemotherapy improve survival, these treatments can adversely affect cognitive function, quality of life,...

10.1093/neuonc/noae259 article EN other-oa Neuro-Oncology 2024-12-25

Teflon injection has been used for vocal fold medialization following paralysis. Recently, numerous articles have discussed the complications of injection, including overinjection, airway obstruction. granuloma, and an abnormal mass effect creating a decreased vibratory character true fold. Multiple techniques removal described. This report details our experience with complete granuloma via lateral laryngotomy under local anesthesia. Microscopic dissection entire paraglottic space was...

10.1177/000348949810700901 article EN Annals of Otology Rhinology & Laryngology 1998-09-01

Abstract Background Despite recent advances in the biology of IDH-wildtype glioblastoma, it remains a devastating disease with median survival less than 2 years. However, molecular underpinnings heterogeneous response to current standard-of-care treatment regimen consisting maximal safe resection, adjuvant radiation, and chemotherapy temozolomide remain unknown. Methods Comprehensive histopathologic, genomic, epigenomic evaluation paired initial recurrent glioblastoma specimens from 106...

10.1093/neuonc/noae214 article EN cc-by-nc Neuro-Oncology 2024-10-09

Glioblastoma is the most aggressive adult primary brain cancer, characterized by significant heterogeneity, posing challenges for patient management, treatment planning, and clinical trial stratification.

10.1093/neuonc/noae260 article EN Neuro-Oncology 2024-12-12

Abstract PURPOSE Glioblastoma is the most prevalent primary malignant brain tumor in adults, with a median overall survival (OS) of approximately 15 months and only limited advancements prognostication prediction. This study aims to evaluate an AI-based prognostic stratification model for OS prediction trained on ReSPOND consortium data validate its performance independent dataset. METHODS The AI was cohort 2,293 glioblastoma patients from 22 institutions across three continents. For...

10.1093/neuonc/noad179.0709 article EN Neuro-Oncology 2023-11-01

Prior characterization of treatment-effect and tumor recurrence using deep learning approaches have not optimized for spatial classification within a single lesion, which could improve surgical planning treatment. 10mm patches pre-surgical anatomical physiological images surrounding the locations histopathologically-confirmed tissue samples were used to train our models. Including images, pretraining on unlabeled data in an autoencoding task, training with alternative cross-validation...

10.58530/2023/0132 article EN Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific Meeting and Exhibition/Proceedings of the International Society for Magnetic Resonance in Medicine, Scientific Meeting and Exhibition 2024-08-14

This study aimed to perform indirect detection of deuterated glucose metabolism at 3 Tesla in healthy subjects and patients with brain tumors using time-series data acquired from atlas-based single-voxel spectroscopy whole-brain 3D magnetic resonance spectroscopic imaging (MRSI). Following 2H-glucose consumption, generally displayed reduced levels glutamate the anterior cingulate cortex (ACC) midline gray matter, while patient T2 lesions did not appear show same trend. These preliminary...

10.58530/2023/2502 article EN Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific Meeting and Exhibition/Proceedings of the International Society for Magnetic Resonance in Medicine, Scientific Meeting and Exhibition 2024-08-14

Hyperpolarized [1-13C]alpha-ketoglutarate (aKG) is a metabolic probe that can provide direct access to the pathway for glutamate production or 2-HG in altered alpha-ketoglutarate metabolism via IDH mutations. With its potential serve as biomarker of IDH1 mutational status glioma and measure aKG normal healthy subjects, we developed new chemistry preparation standard operating procedure (SOP) on-site hyperpolarized GMP characterized investigate feasibility this clinical setting. Following...

10.58530/2023/0843 article EN Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific Meeting and Exhibition/Proceedings of the International Society for Magnetic Resonance in Medicine, Scientific Meeting and Exhibition 2024-08-14

<h3>Background</h3> High tumor heterogeneity and low mutational burden in cancers pose significant challenges for immunotherapy. To address this, we developed a novel <i>in silico</i> pipeline to characterize cancer-specific splicing events (neojunctions) expressed ubiquitously across ten cancer types. This approach successfully identified tumor-wide, public, alternatively neoantigens (ASNs) that elicit CD8+ T-cell-mediated cytotoxicity multiple cancers. <h3>Methods</h3> Our SSNIP recurring...

10.1136/jitc-2024-sitc2024.0154 article EN cc-by-nc Regular and Young Investigator Award Abstracts 2024-11-01

Abstract BACKGROUND Machine-learning models have demonstrated great promise in predicting tumor infiltration beyond anatomical margins glioblastoma. Yet standard-of-care (SOC) radiation therapy (RT) planning only utilizes a uniform, isotropic 2cm-expansion of the T1-post-contrast-lesion or T2-lesion to generate clinical target volume (CTV), without considering heterogeneity infiltration. We hypothesize that using novel deep-learning approach predict regions progression with metabolic and...

10.1093/neuonc/noae165.0838 article EN Neuro-Oncology 2024-11-01
Coming Soon ...